IL7R and acute lymphoblastic leukemia: This novel therapeutic approach is also supported by other evidence, mainly proved in T-ALL cases with the finding that early T-cell precursor (ETP) ALL patients with JAK/STAT pathway activation, independently from the presence of JAK/STAT mutations [38], are sensitive to ruxolitinib [39], and that the treatment of IL7R mutant T-ALL cell line or PDX samples with ruxolitinib in combination with dexamethasone has a synergistic effect [40].